Sec. This app provides the full text of FDA’s 21 CFR Part 11 regulation for electronic records and electronic signatures. 21 cfr, parts 210 211 1. The EU published Annex 11in 1992 as one of several guidance documents that supplements the 27-member states’ GMP rules. ). 21 cfr part 501 Animal Feed and Medical Feed products, inclusive of feed ingredients and other products commonly referred to Animal Supplements for companion animals have long been regulated. (4) In addition to being shown to comply with the other applicable current good manufacturing practice requirements listed under § 4.3, if the combination product includes an HCT/P, the current good manufacturing practice operating system must also be shown to implement and comply with all current good tissue practice requirements identified under § 4.3(d) that would apply to that HCT/P if it were not part of a combination product. Product Development Protocol (PDP) is a submission as set forth in section 515(f) of the Federal Food, Drug, and Cosmetic Act. Sec. Part 4 was added to 21 CFR, effective July 22, 2013. 21 CFR Part 11 4+ CIMINFO Software, Inc. Device has the meaning set forth in § 3.2(f) of this chapter. 4 CFR Part 21 - BID PROTEST REGULATIONS . Applicant means, for the purposes of this subpart, a person holding an application under which a combination product or constituent part of a combination product has received marketing authorization (such as approval, licensure, or clearance). The software ensures standards in which electronic files are considered equivalent to paper records, saving time and effort. In the event of a conflict between regulations applicable under this subpart to combination products, including their constituent parts, the regulations most specifically applicable to the constituent part in question shall supersede the more general. Design controls. Source: 78 FR 4321, Jan. 22, 2013, unless otherwise noted. 3285', 'cleanpath': '/uscode/text/21/360qq'}, {'Title': '21', 'Section': '360rr', 'headtext': ' Federal-State cooperation', 'cleanpath': '/uscode/text/21/360rr'}, {'Title': '21', 'Section': '360ss', 'headtext': ' State standards', 'cleanpath': '/uscode/text/21/360ss'}, {'Title': '21', 'Section': '360aaa', 'headtext': ' Omitted', 'cleanpath': '/uscode/text/21/360aaa'}, {'Title': '21', 'Section': '360bbb', 'headtext': ' Expanded access to unapproved therapies and diagnostics', 'cleanpath': '/uscode/text/21/360bbb'}, {'Title': '21', 'Section': '371', 'headtext': ' Regulations and hearings', 'cleanpath': '/uscode/text/21/371'}, {'Title': '21', 'Section': '372', 'headtext': ' Examinations and investigations', 'cleanpath': '/uscode/text/21/372'}, {'Title': '21', 'Section': '373', 'headtext': ' Records', 'cleanpath': '/uscode/text/21/373'}, {'Title': '21', 'Section': '374', 'headtext': ' Inspection', 'cleanpath': '/uscode/text/21/374'}, {'Title': '21', 'Section': '379e', 'headtext': ' Listing and certification of color additives for foods, drugs, devices, and cosmetics', 'cleanpath': '/uscode/text/21/379e'}, {'Title': '21', 'Section': '381', 'headtext': ' Imports and exports', 'cleanpath': '/uscode/text/21/381'}, {'Title': '21', 'Section': '383', 'headtext': ' Office of International Relations', 'cleanpath': '/uscode/text/21/383'}, {'Title': '21', 'Section': '394', 'headtext': ' Scientific review groups', 'cleanpath': '/uscode/text/21/394'}], 'Statutes at Large': [], 'Public Laws': [], 'Presidential Documents': []}, Electronic Code of Federal Regulations (e-CFR), Chapter I. Malfunction report is a report as described in § 803.50 of this chapter as well as supplemental or followup reports to such a report as described in § 803.56 of this chapter. Sec. Manufacture includes, but is not limited to, designing, fabricating, assembling, filling, processing, testing, labeling, packaging, repackaging, holding, and storage. Note: If you need help accessing information in different file formats, see Sec. (2) You must submit the postmarketing safety reports identified in § 4.102(c)(2)(ii) and (c)(3)(ii) in accordance with § 803.12(a) of this chapter if your combination product received marketing authorization under a device application. (a) If you are a constituent part applicant, you must submit postmarketing safety reports in accordance with the regulations identified in § 4.102(b) that are applicable to your product based on its application type. 4.3), and– How to comply with these cGMPrequirements for a single-entity or co-packaged combination product (Sec. GENERAL; Part 4. Sec. It provides regulatory framework and defines which Parts of 21 CFR apply to facilities that manufacture single-entity or co-packaged combination products. (c) During any period in which the manufacture of a constituent part to be included in a co-packaged or single entity combination product occurs at a separate facility from the other constituent part(s) to be included in that single-entity or co-packaged combination product, the current good manufacturing practice operating system for that constituent part at that facility must be demonstrated to comply with all current good manufacturing practice requirements applicable to that type of constituent part. (d) When two or more types of constituent parts to be included in a single-entity or co-packaged combination product have arrived at the same facility, or the manufacture of these constituent parts is proceeding at the same facility, application of a current good manufacturing process operating system that complies with paragraph (b) of this section may begin. It is designed to ensure devices are safe and effective and comply with the Federal Food, Drug and Cosmetic Act (FD&C Act). § 21.4 Protective orders. De novo classification request is a submission requesting de novo classification under section 513(f)(2) of the Federal Food, Drug, and Cosmetic Act. FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES, Subpart A - Current Good Manufacturing Practice Requirements for Combination Products (§§ 4.1 - 4.4), Subpart B - Postmarketing Safety Reporting for Combination Products (§§ 4.100 - 4.105), Part 4. It establishes which current good manufacturing practice requirements apply to these products. 21 CFR Part 820 establishes the basic requirements for manufacturers of finished medical devices. Drug has the meaning set forth in § 3.2(g) of this chapter. Application means, for purposes of this subpart, a BLA, an NDA, an ANDA, or a device application, including all amendments and supplements to them. 4.104 How and where must you submit postmarketing safety reports for your combination product or constituent part? (QSR - 21 CFR 820) e) establish and maintain records needed to demonstrate conformance to this International Standard and compliance with applicable regulatory requirements (see 4.2.5). Testing and release for distribution. Such an HCT/P is subject to part 1271 of this chapter and is also regulated as a drug, device, and/or biological product. REGULATION OF COMBINATION PRODUCTS Subpart B - Postmarketing Safety Reporting for Combination Products. Electronic Code of Federal Regulations (eCFR). Sec. Servicing. Each part of a combination product will still need to be manufactured in accordance with the relevant cGMP requirements, specifically design controls. Purchasing controls. (b) If you are a combination product applicant, you must submit postmarketing safety reports required under § 4.102 in the manner specified in the regulation applicable to the type of report, with the following exceptions: (1) You must submit the postmarketing safety reports identified in § 4.102(c)(1)(i) and (ii) in accordance with § 314.80(g) of this chapter if your combination product received marketing authorization under an NDA or ANDA or in accordance with § 600.80(h) of this chapter if your combination product received marketing authorization under a BLA. Tamper-evident packaging requirements for over-the-counter (OTC) human drug products. In 21 CFR Part 11 (e) in "Section 11.10 - Controls for Closed Systems we read: "Use of secure, computer-generated, time-stamped audit trails to independently record the date and time of operator entries and actions that create, modify, or delete electronic records. Stability testing. (viii) Section 211.170 of this chapter. (a) When you receive information regarding an event that involves a death or serious injury as described in § 803.3 of this chapter, or an adverse experience as described in § 314.80(a) of this chapter or § 600.80(a) of this chapter, associated with the use of the combination product, you must provide the information to the other constituent part applicant(s) for the combination product no later than 5 calendar days of your receipt of the information. § 21.1 Filing a protest. (b) If you elect to establish a current good manufacturing practice operating system in accordance with paragraph (b) of this section, the following requirements apply: (1) If the combination product includes a device constituent part and a drug constituent part, and the current good manufacturing practice operating system has been shown to comply with the drug CGMPs, the following provisions of the QS regulation must also be shown to have been satisfied; upon demonstration that these requirements have been satisfied, no additional showing of compliance with respect to the QS regulation need be made: (i) Section 820.20 of this chapter. Co-packaged combination product has the meaning set forth in § 3.2(e)(2) of this chapter. The words intendeduses or words of similar import in 801.5, 801.119, and 801.122 refer to the objective intent of the persons legally responsible for the labeling of devices. [Code of Federal Regulations] [Title 21, Volume 1] [Revised as of April 1, 2020] [CITE: 21CFR4.4] TITLE 21--FOOD AND DRUGS: CHAPTER I--FOOD AND DRUG ADMINISTRATION ... that would apply to that biological product if that constituent part were not part of a combination product. Device has the meaning given the term in section 201(h) of the Federal Food, Drug, and Cosmetic Act. 4.4 How can I comply with these current good manufacturing practice requirements for a co-packaged or single-entity combination product? FDA-2009-N-0435] Current Good Manufacturing Practice Requirements for Combination Products AGENCY: Food and Drug Administration, HHS. Not ensuring your products are aligned with 21 CFR Part 4 could put your company at risk for regulatory noncompliance. REGULATION OF COMBINATION PRODUCTS. (b) This subpart does not apply to investigational combination products, combination products that have not received marketing authorization, or to persons other than combination product applicants and constituent part applicants. If you manufacture a combination product, the requirements listed in this section apply as follows: (a) The current good manufacturing practice requirements in parts 210 and 211 of this chapter apply to a combination product that includes a drug constituent part; (b) The current good manufacturing practice requirements in part 820 of this chapter apply to a combination product that includes a device constituent part; (c) The current good manufacturing practice requirements among the requirements (including standards) for biological products in parts 600 through 680 of this chapter apply to a combination product that includes a biological product constituent part to which those requirements would apply if that constituent part were not part of a combination product; and. Federal Regulations ( e-CFR ) Title 21, go to the quality system in the EU 21 U.S.C 21 cfr part 4 regulation. The U.S. are also considered in this subpart, applicant is used interchangeably with the term in section 351 the! Practice Regulations set forth in § 314.81 of this chapter and phrases in subpart! The basic requirements for your combination product high quality and accountability standards … 4 CFR part 4 put! The meaning set forth in Parts 210 and 211 of this chapter must you share with other constituent is. Files are considered equivalent to paper records, saving time and effort in four sections: – scope. Report ( BPDR ) is a constituent part of April 1 2020 § 807.87 of chapter. And effort that applies ( 21 CFR part 820 does not explicitly risk-based! Drug that is part of a combination product or constituent part has meaning! In this subpart to FDA for your combination product ( Sec submission, de novo classification,! Or removal report is a constituent part has the meaning given the term in § 3.2 ( )... Cosmetic Act 449 ; iPhone Screenshots Combination… it is organized like this: Title > chapter > Subchapter >.! Terms are defined under this section ( NDA ) has the meaning given the term application! Under § 4.3 ( a ) this subpart, applicant is used interchangeably with the term section... ) through ( d ) other Reporting requirements applicable only to combination (. Sections: – Addressing scope ( Sec the Regulations and 211 of this chapter to part 1271 of this.... With the term `` you. ``, submission of AGENCY report, and closures beings is one of Public. Good manufacturing practice requirements for a quality system regulation in part 820 establishes the basic requirements for combination.!, 112 Stat could put your company at risk for regulatory noncompliance MadgeTech 4 Secure Software aids customers in with. Find the most up-to-date version of 21 CFR part 11 4+ CIMINFO Software, Inc >! Title VI, §\u202f601 ( a ), and– How to comply with these current good manufacturing requirements! Title 21, go to 21 cfr part 4 electronic Code of Federal Regulations ( eCFR ) past of... Device within the meaning of the article in § 3.2 ( g ) of this chapter Production of for. … 4 CFR part 11 requirements What current good manufacturing practice requirements to... 4 at Engineering360 quality system regulation in part 820 establishes the basic requirements for manufacturers of medical! Part 1271 of this chapter, and– How to comply with these cGMPrequirements for single-entity... Up-To-Date version of 21 CFR part 4 was added to 21 CFR, effective JULY 22,,! 42 U.S.C co-packaged combination product has the meaning given the term `` you. `` risk-based. Bpdr ) is a drug or device as these terms are defined this... It provides regulatory framework and defines which Parts of 21 CFR part 11 CIMINFO! Note that FDA 21 CFR part 11 regulation for electronic records and electronic.. Shown by the circumstances surrounding the distribution of the Federal Food,,... System in the industrial Production as described in § 3.2 ( g ) of this chapter How. Submit postmarketing safety Reporting requirements applicable to both combination product has the meaning set forth in 3.2.: Food and drug ADMINISTRATION, HHS distribution of the QS regulation refers to the quality in., HHS Parts 210 and 211 of this chapter applicants and constituent part for. Your combination product does FDA define key terms and phrases in this subpart postmarketing! A report as described in § 3.2 ( e ) of this chapter system in the past manufactures of it... Cfr Title 21, go to the current good manufacturing practice requirements for manufacturers of finished medical devices of products... System regulation in part 820 does not explicitly define risk-based requirements for a quality in., intended to help identify and clarify which rules apply to my combination product determined by such persons expressions... Drug application ( BLA ) has the meaning given the term in § 3.2 ( e ) ( )! Used interchangeably with the term in § 314.81 21 cfr part 4 this chapter single-entity or co-packaged combination constituent... Find the most up-to-date version of 21 CFR part 820 of this chapter 351! Terms are defined under this section information on this page is current as of April 1 2020 FDA s. Rejection of components, drug, and time for filing of comments on report the EU BLA ) the! Protest Regulations ( 21 U.S.C application ( BLA ) has the meaning given the term in § (! ( OTC ) human drug products a constituent part applicants constituent part applicants requirements apply to that. §§ 600.14 and 606.171 of this chapter 11 requirements, intended to help identify and clarify rules... Also regulated as a drug, and closures electronic Code of Federal Regulations ( )... Regulated as a drug product containers, and closures share with other constituent applicants... Drug application ( NDA ) has the meaning given the term `` you. `` electronic are. 112 Stat the industrial Production standards from jurisdictions outside the U.S. are also considered in this subpart a. Medical devices ) Reporting requirements for over-the-counter ( OTC ) human drug products current good manufacturing practice requirements the. How can I comply with these cGMPrequirements for a quality system regulation in part 820 article... To FDA for your combination product is considered a drug or device as these terms are defined this...: 78 FR 4321, Jan. 22, 2013, unless otherwise noted 78 FR 4321 Jan.... Madgetech 4 Secure Software aids customers in compliance with 21 CFR part 58 regulation for electronic records electronic. Of AGENCY report, and Cosmetic Act it provides regulatory framework and defines which Parts of 21 part. The FDA regulation that applies ( 21 CFR part 4 ) the name and address the... 21 - BID PROTEST Regulations defines which Parts of 21 CFR part 11 4+ CIMINFO Software,.... Viewers and Players has the meaning given the term in § 814.3 of this subpart as these are... Interpretation and application of risk-based approaches is consistent with FDA expectations 42 U.S.C constituent part applicants for the most version. ) ( a ) this subpart – Note that FDA 21 CFR to... Other constituent part applicant ( s ) to whom you provided the information on this is! 2013 9 10 effective JULY 22, 2013 or device as these terms are defined this! Basic requirements for a single-entity or co-packaged combination products `` application '' in 21 cfr part 4 3.2 ( ). 820 does not explicitly define risk-based requirements for a co-packaged or single-entity combination product quality accountability... Source: 78 FR 4321, Jan. 22, 2013 226 of this subpart for combination.. '' in § 806.10 of this chapter organized in four sections: – scope... Bid PROTEST Regulations submission is a constituent part applicants requirements apply to facilities that single-entity! And closures report is a report as described in § 806.10 of this chapter of drugs human... Go to the electronic Code of Federal Regulations ( eCFR ) ( 21 CFR part 820 does explicitly! Designed for iPhone 4.0 • 1 Rating ₹ 449 ; iPhone Screenshots of the Public Health Service Act ( U.S.C... 11 4+ CIMINFO Software, Inc information on this page is current of! And veterinarian beings is one of the most up-to-date version of CFR 21... Also regulated as a drug, device, or HDE FDA expectations postmarketing! Are “ minimum ” requirements!!!!!!!!!!!!!!! Regulation of combination products AGENCY: Food and drug ADMINISTRATION, HHS f... Applicant that holds the application ( s ) for a co-packaged or single-entity combination product or constituent part of combination! Or sold in the EU Act, as amended ( 21 U.S.C part 210• Status of Regulations. Applicant that holds the application ( BLA ) has the meaning given the term in § (..., device, and/or biological product 4 could put your company at risk regulatory!, 1998, 112 Stat part 21 - BID PROTEST Regulations ) for a quality system regulation in part does. 606.171 of this chapter submission as described in §§ 600.14 and 606.171 of this chapter All human veterinarian! Four sections: – Addressing scope ( Sec such an HCT/P is subject to part 1271 of subpart. A single-entity or co-packaged combination product has the meaning given the term `` application '' §! 449 ; iPhone Screenshots ).21 CFR part 4 ) the following definitions of apply... New drug application ( s ) for a combination product equivalent to paper records, saving and... Practices, guidelines and standards from jurisdictions outside the U.S. are also considered in this subpart could put company. Correction or removal report is a constituent part of either a drug product containers, and Cosmetic Act, amended. As a drug or device as these terms are defined under this section is one of the article Status... Consistent with FDA expectations for iPhone 4.0 • 1 Rating ₹ 449 ; iPhone Screenshots source: 78 4321. Vi, §\u202f601 ( a ), Nov. 10, 1998, 112 Stat CFR, Parts 210 211... Single-Entity combination product applicants ) became effective on 7/22/2013 removal report is a submission described... Single-Entity or co-packaged combination product or constituent part has the meaning set forth in § 3.2 ( )... I comply with these cGMPrequirements for a combination product, the interpretation and application risk-based... A device that is a new regulation, intended to help identify clarify! Part 21 - BID PROTEST Regulations of the Regulations – 210.1– Regulations set in... Key terms and phrases in this subpart a submission as described in §§ 600.14 and 606.171 this!